These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1215 related articles for article (PubMed ID: 15664014)
21. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309 [TBL] [Abstract][Full Text] [Related]
22. Regulation of osteoclastogenesis by gap junction communication. Matemba SF; Lie A; Ransjö M J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710 [TBL] [Abstract][Full Text] [Related]
23. Prostate cancer mediates osteoclastogenesis through two different pathways. Inoue H; Nishimura K; Oka D; Nakai Y; Shiba M; Tokizane T; Arai Y; Nakayama M; Shimizu K; Takaha N; Nonomura N; Okuyama A Cancer Lett; 2005 Jun; 223(1):121-8. PubMed ID: 15890244 [TBL] [Abstract][Full Text] [Related]
24. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250 [TBL] [Abstract][Full Text] [Related]
25. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Ishii T; Ohshima S; Ishida T; Mima T; Tabunoki Y; Kobayashi H; Maeda M; Uede T; Liaw L; Kinoshita N; Kawase I; Saeki Y Biochem Biophys Res Commun; 2004 Apr; 316(3):809-15. PubMed ID: 15033472 [TBL] [Abstract][Full Text] [Related]
26. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Aubin JE; Bonnelye E Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853 [TBL] [Abstract][Full Text] [Related]
27. A role for the immunomodulatory molecules CD200 and CD200R in regulating bone formation. Lee L; Liu J; Manuel J; Gorczynski RM Immunol Lett; 2006 Jun; 105(2):150-8. PubMed ID: 16530849 [TBL] [Abstract][Full Text] [Related]
28. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680 [TBL] [Abstract][Full Text] [Related]
29. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. Clohisy DR; Ramnaraine ML; Scully S; Qi M; Van G; Tan HL; Lacey DL J Orthop Res; 2000 Nov; 18(6):967-76. PubMed ID: 11192258 [TBL] [Abstract][Full Text] [Related]
30. [New paradigms in the regulation of bone metabolism]. Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485 [TBL] [Abstract][Full Text] [Related]
32. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis. Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523 [TBL] [Abstract][Full Text] [Related]
33. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Sordillo EM; Pearse RN Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579 [TBL] [Abstract][Full Text] [Related]
34. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Pang M; Martinez AF; Fernandez I; Balkan W; Troen BR Gene; 2007 Nov; 403(1-2):151-8. PubMed ID: 17897792 [TBL] [Abstract][Full Text] [Related]
35. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109 [TBL] [Abstract][Full Text] [Related]
36. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. Ueno Y; Shinki T; Nagai Y; Murayama H; Fujii K; Suda T J Cell Biochem; 2003 Oct; 90(2):267-77. PubMed ID: 14505343 [TBL] [Abstract][Full Text] [Related]
37. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398 [TBL] [Abstract][Full Text] [Related]
38. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. Xing L; Carlson L; Story B; Tai Z; Keng P; Siebenlist U; Boyce BF J Bone Miner Res; 2003 Feb; 18(2):260-9. PubMed ID: 12568403 [TBL] [Abstract][Full Text] [Related]
39. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. Yamada N; Tsujimura T; Ueda H; Hayashi S; Ohyama H; Okamura H; Terada N Cytokine; 2005 Aug; 31(4):288-97. PubMed ID: 15996478 [TBL] [Abstract][Full Text] [Related]